Australia's most trusted
source of pharma news
Friday, 19 April 2024
Posted 10 August 2022 PM
Adelaide-based Mayne Pharma has announced a deal to sell Metrics Contract Services to Catalent for US$475 million, around AU$679 million, as it focuses on growth portfolios.
It's a nice profit for Mayne, which bought Metrics in 2012 for US$105-120 million. At the time Mayne CEO, Scott Richards, said the business brought additional technical capabilities and cross-selling opportunities.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.